Melanoma

Vaccine Data from Largest-Ever Study Presented

Published in Vaccine Weekly, March 8th, 2000

Corixa Corporation, Seattle, Washington, announced that data from a Phase III, randomized trial to evaluate Corixa's therapeutic vaccine for the treatment of melanoma, Melacine, were presented February 17, 2000, by the Southwest Oncology Group at the "Melanoma at the Millennium" meeting in Phoenix, Arizona.

In his presentation on behalf of the Southwest Oncology Group, Dr. Vernon Sondak of the University of Michigan reported results indicating that Corixa's Melacine vaccine may benefit patients, in particular those with thinner tumors.

The Phase III clinical trial was designed by the Southwest Oncology Group with the primary study endpoint being the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry